The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Open accessAbstract
There is no standard treatment for patients with unresectable hepatocellular carcinoma (HCC). Survival benefits derived from medical interventions are controversial. The aim of this systematic review was to assess the evidence of the impact of medical treatments on survival. Randomized controlled trials (RCTs) that were published as full papers assessing survival for primary treatments of HCC were included. MEDLINE, the Cochrane Library, CANCERLIT, and a manual search from 1978 to May 2002 were used. The primary end point was survival, and the secondary end point was response to treatment. Estimates of effect were calculated according to the random effects model. Sensitivity analysis included methodological quality. We identified 61 randomized trials, but only 14 met the criteria to perform a meta-analysis assessing arterial embolization (7 trials, 545 patients) or tamoxifen (7 trials, 898 patients). Arterial embolization improved 2-year survival compared with control (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.32-0.89; P = .017). Sensitivity analysis showed a significant benefit of chemoembolization with cisplatin or doxorubicin (OR, 0.42; 95% CI, 0.20-0.88) but none with embolization alone (OR, 0.59; 95% CI, 0.29-1.20). Overall, treatment induced objective responses in 35% of patients (range, 16%-61%). Tamoxifen showed no antitumoral effect and no survival benefits (OR, 0.64; 95% CI, 0.36-1.13; P = .13), and only low-quality scale trials suggested 1-year improvement in survival. In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationPrognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Self-citationEstimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationImproving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
“Radiofrequency ablation 17 (6) 12 (4) Radiotherapy** 13 (4) 15 ( 5 )”
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Sensitivity analysis showed a significant benefit of chemoembolization with cisplatin or doxorubicin in four studies, but none with embolization alone in three studies [139].”
BackgroundMethodInfluentialVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Self-citationAASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationRandom-effects model for meta-analysis of clinical trials: An update
DerSimonian, R., & Kacker, R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.04.004 · Cited by 2,374
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“Meta-analyses of RCTs comparing TACE and best supportive care demonstrate significant improvements in OS among patients with BCLC Stage B HCC, [ 284 ] leading to adoption of TACE in management guidelines.”
Self-citationMolecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Self-citationEvidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Self-citationDesign and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationLammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., et al. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9711-7 · Cited by 1,557
Hepatocellular carcinoma: clinical frontiers and perspectives
Bruix, J., Gores, G. J., & Mazzaferro, V. (2014) · Gut · doi:10.1136/gutjnl-2013-306627 · Cited by 1,364
Self-citationHepatocellular carcinoma: a review
Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,185
Diagnosis and Treatment of Hepatocellular Carcinoma
El-Serag, H. B., Marrero, J. A., Rudolph, L., & Reddy, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.090 · Cited by 1,137
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Self-citationHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,048
Self-citationOmata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Self-citationHepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Self-citationVarela, M., Real, M. I., Burrel, M., Forner, A., Sala, M., Brunet, M., Ayuso, C., Castells, L., Montañá, X., Llovet, J. M., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.020 · Cited by 941
Self-citationAASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
“Several other treatments have not shown any relevant survival benefit (immunotherapy, internal radiation, tamoxifen, or antiandrogen agents) or are currently under investigation (tyrosine kinase inhibitors, antiangiogenic agents, gene therapy).(35) Table 1 Evidence-Based Benefits in the Treatment of Hepatocellular Car…”
BackgroundSelf-citationVilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G.-P., Sibert, A., Bouattour, M., Lebtahi, R., Allaham, W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30683-6 · Cited by 834
Bujold, A., Massey, C. A., Kim, J. J., Brierley, J., Cho, C., Wong, R. K. S., Dinniwell, R. E., Kassam, Z., Ringash, J., Cummings, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1659 · Cited by 820
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Self-citationMicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., Ambs, S., Chen, Y., Meltzer, P. S., Croce, C. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901282 · Cited by 802
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Marelli, L., Stigliano, R., Triantos, C., Senzolo, M., Cholongitas, E., Davies, N., Tibballs, J., Meyer, T., Patch, D. W., & Burroughs, A. K. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-006-0062-3 · Cited by 791
Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. H. (2016) · Hepatology · doi:10.1002/hep.28453 · Cited by 732
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Self-citationLencioni, R., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., Paik, S. W., Reig, M., Kim, D. Y., Chau, G.-Y., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.012 · Cited by 694
Self-citationSalem, R., Gordon, A. C., Mouli, S., Hickey, R., Kallini, J., Gabr, A., Mulcahy, M. F., Baker, T., Abecassis, M., Miller, F. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.029 · Cited by 691
mRECIST for HCC: Performance and novel refinements
Llovet, J. M., & Lencioni, R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.026 · Cited by 680
Self-citationThe diagnosis and treatment of hepatocellular carcinoma
Hartke, J., Johnson, M., & Ghabril, M. (2017) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.12.011 · Cited by 670
Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., Paprottka, P. M., Fiore, F., Van Buskirk, M., Bilbao, J. I., et al. (2011) · Hepatology · doi:10.1002/hep.24451 · Cited by 652
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Raoul, J.-L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baere, T. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.11.002 · Cited by 643
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Self-citationKulik, L. M., Carr, B. I., Mulcahy, M. F., Lewandowski, R. J., Atassi, B., Ryu, R. K., Sato, K. T., Benson, A., Nemcek, A. A., Gates, V. L., et al. (2008) · Hepatology · doi:10.1002/hep.21980 · Cited by 620
de Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Self-citationon behalf of the PRECISION ITALIA STUDY GROUP, Golfieri, R., Giampalma, E., Renzulli, M., Cioni, R., Bargellini, I., Bartolozzi, C., Breatta, A. D., Gandini, G., Nani, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.199 · Cited by 606
Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600
Self-citationLee, T. K. W., Castilho, A., Cheung, V. C. H., Tang, K. H., Ma, S., & Ng, I. O. L. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.005 · Cited by 586
Lewandowski, R. J., Kulik, L. M., Riaz, A., Senthilnathan, S., Mulcahy, M. F., Ryu, R. K., Ibrahim, S. M., Sato, K. T., Baker, T., Miller, F. H., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02695.x · Cited by 582
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Chemoembolization for hepatocellular carcinoma
Bruix, J., Sala, M., & Llovet, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.032 · Cited by 569
Self-citationImmunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Parikh, T., Drew, S. J., Lee, V. S., Wong, S., Hecht, E. M., Babb, J. S., & Taouli, B. (2008) · Radiology · doi:10.1148/radiol.2463070432 · Cited by 560
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Self-citationRaoul, J.-L., Sangro, B., Forner, A., Mazzaferro, V., Piscaglia, F., Bolondi, L., & Lencioni, R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.006 · Cited by 537
Peng, Z.-W., Zhang, Y.-J., Chen, M.-S., Xu, L., Liang, H.-H., Lin, X.-J., Guo, R.-P., Zhang, Y.-Q., & Lau, W. Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9936 · Cited by 531
Local-Regional Treatment of Hepatocellular Carcinoma
Lencioni, R., & Crocetti, L. (2012) · Radiology · doi:10.1148/radiol.11110144 · Cited by 514
Sergio, A., Cristofori, C., Cardin, R., Pivetta, G., Ragazzi, R., Baldan, A., Girardi, L., Cillo, U., Burra, P., Giacomin, A., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01712.x · Cited by 512
Loco‐regional treatment of hepatocellular carcinoma†
Lencioni, R. (2010) · Hepatology · doi:10.1002/hep.23725 · Cited by 509
Updated treatment approach to hepatocellular carcinoma
Llovet, J. M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1566-3 · Cited by 508
Self-citationMeyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30156-5 · Cited by 499
Burrel, M., Reig, M., Forner, A., Barrufet, M., Lope, C. R. D., Tremosini, S., Ayuso, C., Llovet, J. M., Real, M. I., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.008 · Cited by 485
Self-citationZhao, T., Tang, H., Xie, L., Zheng, Y., Ma, Z., Sun, Q., & Li, X. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13129 · Cited by 478
ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions
Marrero, J. A., Ahn, J., & Reddy, R. K. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.213 · Cited by 477
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxì, A., & Cammà, C. (2010) · Hepatology · doi:10.1002/hep.23485 · Cited by 473
Self-citationCho, Y. K., Kim, J. K., Kim, M. Y., Rhim, H., & Han, J. K. (2009) · Hepatology · doi:10.1002/hep.22648 · Cited by 466
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Self-citationHepatocellular carcinoma review: Current treatment, and evidence-based medicine
Raza, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4115 · Cited by 464
Hepatocellular carcinoma: From diagnosis to treatment
Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A., & Pawlik, T. M. (2016) · Surgical Oncology · doi:10.1016/j.suronc.2016.03.002 · Cited by 456
Hepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Self-citationSala, M., Llovet, J. M., Vilana, R., Bianchi, L., Solé, M., Ayuso, C., Brú, C., & Bruix, J. (2004) · Hepatology · doi:10.1002/hep.20465 · Cited by 447
Self-citationForner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J. (2009) · Cancer · doi:10.1002/cncr.24050 · Cited by 426
Self-citationTrial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Self-citationPoon, D., Anderson, B. O., Chen, L.-T., Tanaka, K., Lau, W. Y., Van Cutsem, E., Singh, H., Chow, W. C., Ooi, L. L., Chow, P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70241-4 · Cited by 410
Hepatocellular Carcinoma: The Need for Progress
Thomas, M. B., & Zhu, A. X. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.196 · Cited by 406
Ricke, J., Klümpen, H. J., Amthauer, H., Bargellini, I., Bartenstein, P., de Toni, E. N., Gasbarrini, A., Pech, M., Peck-Radosavljevic, M., Popovič, P., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.006 · Cited by 397
Pomfret, E. A., Washburn, K., Wald, C., Nalesnik, M. A., Douglas, D., Russo, M., Roberts, J., Reich, D. J., Schwartz, M. E., Mieles, L., et al. (2010) · Liver Transplantation · doi:10.1002/lt.21999 · Cited by 393
Liu, C.-Y., Chen, K.-F., & Chen, P.-J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021535 · Cited by 391
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationAngiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J.-F. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 372
Kadalayil, L., Benini, R., Pallan, L., O'Beirne, J., Marelli, L., Yu, D., Hackshaw, A., Fox, R., Johnson, P., Burroughs, A. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt247 · Cited by 370
Verslype, C., Rosmorduc, O., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds225 · Cited by 365
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
LOPEZ, P. M., VILLANUEVA, A., & LLOVET, J. M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02932.x · Cited by 344
Self-citation2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Kudo, M., Ren, Z., Guo, Y., Han, G., Lin, H., Zheng, J., Ogasawara, S., Kim, J. H., Zhao, H., Li, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02575-3 · Cited by 342
Self-citationRecent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Chang, Y., Jeong, S. W., Young Jang, J., & Jae Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218165 · Cited by 336
Transarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Sangro, B., Kudo, M., Erinjeri, J. P., Qin, S., Ren, Z., Chan, S. L., Arai, Y., Heo, J., Mai, A., Escobar, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02551-0 · Cited by 333
Metadata
- Authors
- Llovet, J. M., & Bruix, J.
- Venue
- Hepatology
- Published
- 2003-02
- Volume
- 37
- Issue
- 2
- Pages
- 429-442
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1975154077
- Cited by
- 3,029
- References
- 57
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.